WO2004059004A2 - Procede d'evaluation quantitative des capacites globales et specifiques de reparation de l'adn d'au moins un milieu biologique, ainsi que ses applications - Google Patents
Procede d'evaluation quantitative des capacites globales et specifiques de reparation de l'adn d'au moins un milieu biologique, ainsi que ses applications Download PDFInfo
- Publication number
- WO2004059004A2 WO2004059004A2 PCT/FR2003/003816 FR0303816W WO2004059004A2 WO 2004059004 A2 WO2004059004 A2 WO 2004059004A2 FR 0303816 W FR0303816 W FR 0303816W WO 2004059004 A2 WO2004059004 A2 WO 2004059004A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasmids
- repair
- dna
- lesions
- plasmid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Definitions
- the present invention relates to a method for quantitatively evaluating the overall and specific DNA repair capacities of a biological medium, by evaluating the excision / resynthesis capacities of said medium as well as to its applications.
- DNA is constantly subjected to endogenous or exogenous attacks leading to the formation of lesions of bases or sugars.
- lesions include:
- - lesions of purine or pyrimidine bases oxidative lesions induced by cell metabolism, and by photosensitization; lesions by formation of chemical additives, which result from the harmful action of numerous genotoxic agents such as the polycyclic hydrocarbons contained in the products of combustion; lesions by formation of metheno-bases or of etheno-bases.
- - DNA double helix structure lesions formation of intra-strand bridging (between two adjacent bases of the same strand) or inter-strand (between two bases located on the homologous strands), generally caused by ultraviolet (formation bridges between pyrimidines, which become dimeric) or bifunctional antitumors, such as cisplatin and intercalating agents, which form stable covalent bonds between the bases carried by the opposite strands.
- - lesions by single-strand or double-strand rupture produced by agents such as ionizing radiation and by the action of free radicals.
- the diversity of the induced lesions is illustrated by the analysis of the stable photo-products detected following irradiation with UN C: next to the pyrimidine dimers due to the formation of a cyclobutane nucleus, it forms between two adjacent pyrimidines, pyrimidines (6-4) pyrimidones.
- the relative proportion of pyrimidine and product dimers (6-4) vary from 10 to 4 to 1.
- Their respective efficacy in the lethal effect and in the mutagenic effect of ultraviolet rays is also different: the dimers have a more important cytotoxic role than the products (6-4), while the opposite is true for the mutagenic effect.
- ionizing radiation ⁇ rays of cobalt 60, for example
- single-strand or double-strand breaks approximately in a ratio of 9 to 1
- numerous adducts of bases losses of bases and at high doses, bridges between DNA and adjacent proteins (chromosomes for example).
- chromosomes chromosomes for example.
- the predominant role of double-strand break in the cytotoxic effect of radiation is accompanied by a mutagenic effect due to the alterations of the bases.
- lesions of the photoproduct type (6-4) and pyrimidine dimers of the cyclobutane type are induced by UVC irradiation (Hoeijmaker et al., Mutation Res., 1990, 236, 223-238); oxidative type lesions are induced by the Fenton reaction in the presence of hydrogen peroxide and iron (Elliot et al, Free Rad. Biol. Med, 2000, 1438-1446).
- modified DNA Another means of preparing modified DNA consists in manipulating plasmids by molecular biology techniques and inserting therein an oligonucleotide obtained by chemical synthesis and containing a lesion of interest (Biade et al., J Biol. Chem. , 1997, 273, 898-902).
- the REB system is more specifically dedicated to repairing small DNA lesions such as oxidative damage, abasic sites, basic fragments, base methylations, etheno-bases, etc.
- the REN system takes care of large lesions inducing a distortion of the DNA double helix such as the acetylamino-fluorene, cisplatin and psoralen adducts of DNA, the dimers resulting from UV B irradiation and A C of AD ⁇ , covalent lesions formed between a base of DNA and another molecule, etc. (Sancar et al, Annu. Rev. Genetics, 1995, 29, 69-105).
- this process includes, the elimination of the modified nucleotide and the incorporation, as a replacement, into the DNA chain, of at least one nucleotide triphosphate present in the repair medium.
- the repair systems especially in eukaryotes, are very complex and many variants of this simplistic scheme exist (global repair, repair associated with DNA transcription, repair associated with DNA replication , etc). Some proteins are involved in several repair systems simultaneously, others are specific to a single system, some are inducible by cellular or external factors, others have a ubiquitous and constant expression.
- substrate is used to refer to any DNA capable of undergoing a repair reaction in the presence of cell extract and, by extension, DNA damage.
- biological medium or “cell extract” refers to a biological preparation, purified or not, capable of containing at least one enzyme activity linked to DNA repair.
- a lesion can usually be associated with specific proteins responsible for repairing it in DNA. Differences exist depending on the species; in prokaryotes like Escherichia coli, the enzymes are less specific, while in humans, there is a much more strict association between lesion and specific repair enzyme, especially in the REB systems. For example, Lindahl and Wood (Science, 1999, 286, 1897-1905) describe the most important REB enzymes in humans and the lesions associated with them. For example, in humans, the protein OGG1, which is a glycosylase belonging to the REB system, is associated with the repair of 8-oxo-2 'deoxyguanosine.
- this test includes the use of plasmid DNA into which lesions are introduced (by UV irradiation: formation of pyrimidine dimers, bypasses; by action of DNase I: cut or break single strand); the DNA thus modified is incubated at 30 ° C. in the presence of a repair preparation comprising at least: the cell extract to be evaluated, a nucleotide triphosphate labeled in the alpha position with 32 P and ATP.
- the enzymes in the extract incise the plasmid DNA and eliminate the lesions. DNA is synthesized de novo to replace the removed nucleotides.
- the radioactive nucleotide introduced into the medium is incorporated into DNA during this synthesis.
- the amount of radioactivity incorporated is measured.
- the method of preparation of the cell extract and the reaction conditions intervene in the quality of the repair. In particular, it seems that the best repair yield is obtained with extracts of whole cells of the type used for in vitro transcription, while cytosolic extracts of the type used to promote plasmid replication from 'an SV40 origin as well as other crude cell extracts exhibit nuclease activity, which does not allow a correct interpretation of the repair.
- Wood et al. has been proposed in characterization trials of extracts from cells established from patients suffering from xeroderma pigmentosum (Satoh et al., Proc. Natl. Acad. Sci. USA, 1993, 90, 6335- 6339; Jones et al., Nucl. Acids Res., 1992, 20, 991-995; Robins et al., EMBO J., 1991, 10, 3913-3921).
- Xeroderma pigmentosum is a multigenic, multiallelic, autosomal and recessive disorder. Cells from patients with this disease are very sensitive to ultraviolet light and have defects in DNA repair.
- XPA to XPG Eight genes are involved in the various complementation groups of this disease: XPA to XPG and the variant group XPV. Each group has different characteristics relating to DNA repair and in particular to the different REN subtypes. DNA lesions, whether they belong to the category of small lesions or large lesions, are repaired differently, depending on the complementation group. Other repair diseases (Cockayne syndrome, Ataxia).
- Telangectasia also have their own repair characteristics and have been studied by the method of Wood et al.
- a substrate is added to each well which becomes luminescent after dephosphorylation by alkaline phosphatase.
- the luminescent signal, emitted at each well, is measured. It is proportional to the rate of incorporation of the marker. This method is also described in the International Application
- WO 96/28571 the inventors of which also belong to the team of B. Salles and P. Calsou, and which describes a method for the qualitative and quantitative detection of DNA lesions in which damaged DNA is fixed on a solid support and a composition comprising a cell extract to be tested and containing markers is brought into contact with said injured DNA (before or after attachment to said solid support).
- the repair in the presence of a cell extract is carried out in a reaction medium of 50 ⁇ l, from an extract comprising 150 ⁇ g of proteins, 50 mM of KC1, 5 mM of chloride magnesium, DTT, phosphocreatine, phosphocreatine kinase and various dNTPs, one of which is labeled with digoxygenin.
- the repair is obtained after 3 hours of incubation at 30 ° C and the wells are washed with a washing solution comprising a phosphate buffer with a salt to which a nonionic surfactant (Tween 20) is added in a proportion of 0.05 and 0.15% (preferred composition: 10 mM phosphate buffer, 137 mM NaCl and 0.1% Tween 20) . It is specified that this test is very sensitive, insofar as the detection is carried out on 40 ng of DNA instead of 200 or 300 ng, within the framework of a test in solution.
- a washing solution comprising a phosphate buffer with a salt to which a nonionic surfactant (Tween 20) is added in a proportion of 0.05 and 0.15% (preferred composition: 10 mM phosphate buffer, 137 mM NaCl and 0.1% Tween 20) . It is specified that this test is very sensitive, insofar as the detection is carried out on 40 ng of DNA instead of 200
- A. Redaelli et al. (Terat. Carcinog. Mut., 1998, 18, 17-26) describe a method in which the plasmid is incubated directly with the extract without the nucleotide triphosphate. Cleavages in the supercoiled plasmid cause a change in the rate of migration in the agarose gel during electrophoresis. The super-wound plasmid migrates faster than the incised plasmid, due to its conformation. The bands corresponding to the different forms of the plasmid are quantified; the amount of the incised form is correlated with the incision activity of the lesions of the plasmid, contained in the extract.
- this article studies the incision action of the AP-endonuclease, which intervenes on an abasic site, obtained after the action of a glycosylase specific for the modification to be repaired (alkylation, hydro-deamination lytic, oxidation, mismatch), by cleaving the deoxyribosic phosphodiester link 3 'or 5' from this abasic site.
- the AP-endonuclease activity is more specifically studied on a crude extract of human lymphocytes. The extract (80 ⁇ l) is incubated on the one hand with an undamaged plasmid (control) and on the other hand with a depurinated plasmid. The quantification of the activity of the AP-endonuclease thus appears possible, insofar as the incision activity is dependent on the damage and sensitive to EDTA.
- this method comprises the fixing on a solid support of at least one damaged DNA comprising at least one known lesion; this damaged DNA is then subjected to the action of a repair composition containing or not containing at least one protein involved in the repair of this damaged DNA and the determination of the activity of this protein for repair by measuring the variation of a signal emitted by a marker which is fixed on or removed from the support during the previous step.
- This system which is implemented with damaged DNA which is in the form of an oligonucleotide of 15 to 100 bases or of a polynucleotide of 100 to 20,000 bases, thus allows access to more general information. than the other tests, since the excision of several substrates can be followed simultaneously.
- this method relates to the detection of DNA damage incision activities.
- each test is carried out individually in a tube, that is to say that a reaction is carried out in the presence of a given plasmid and a given extract.
- the rate of incorporation of the marker in the plasmid is compared with the rates of incorporation of marker obtained in a substrate prepared identically in the presence of the control extract.
- the reference control extract is generally prepared from characterized cells transformed with EBV or SV40. It is the same in most of the other variants of the method of Wood et al., Described above.
- the Applicant has set itself the objective of overcoming the drawbacks of the prior art, in particular by proposing a method which makes it possible to characterize and quantify the enzymatic activities of excision / resynthesis of DNA repair in extracts biological of a fast, precise, miniaturized and efficient without the use of control repair solutions.
- the subject of the present invention is a method for quantitative evaluation of the overall and specific DNA repair capacities of at least one biological medium, which method is characterized in that it comprises the following steps:
- step (d) incubating said functionalized support obtained in step (c) with different repair solutions each comprising at least one biological medium capable of containing enzymatic repair activities, ATP, a system for regenerating the ATP, a labeled nucleotide triphosphate and any other component necessary for the activity of the repair enzymes present in said biological medium, preferably at a temperature of 30 ° C for 1 to 5 hours, preferably for 3 hours each of said repair solutions being deposited, prior to said incubation, in each of said distinct and pre-established zones Ai to A x of said functionalized support,
- step (e) at least one washing of said functionalized support, (f) measuring, directly or indirectly, the signal produced by the marker incorporated into the DNA during the repair reaction of step (d), in each of said distinct and pre-established zones Ai to A x ,
- Such a method according to the invention has a certain number of advantages: - It makes it possible to detect an overall effect, by identifying the different lesions, due to the possibility of simultaneously evaluating the repair of different types of lesions.
- the method according to the invention makes it possible to "map" a given biological medium for its enzymatic DNA repair activities. It pe ⁇ net to identify a biological extract according to the card obtained.
- the method according to the invention also allows the comparison of the performances of different biological extracts for repairing DNA lesions.
- the plasmids prepared in step (a) are chosen from those which have a super-coiled double-stranded form (pBR322, M13, pUC, etc.).
- the supercoiled form of the control plasmid is obtained by purification using known techniques, such as, for example, the Qiagen plasmid purification kits. It is also preferable to limit the presence of unwanted forms of plasmid by carrying out other purification steps, such as, for example, centrifugation on cesium chloride and / or on a sucrose gradient.
- the various physical, biological or chemical agents capable of inducing DNA damage are chosen from those which preferably induce: the formation of a single lesion, the formation of a limited number of lesions or the formation of different lesions belonging to the same family.
- Mention may be made, for example, of families of lesions: oxidative lesions, photoproducts induced by ultraviolet B or C, chemical adducts, etheno-bases, abasic sites and DNA breaks.
- the physical and chemical agents are, for example, chosen from those which work mainly:
- singlet oxygen mainly targets guanine; in this case, the very majority lesion formed is 8-oxoguanine (Ravanat et al., Chem. Res. Tox., 1995, 8, 379-388).
- the DNA lesions obtained are oxidative lesions; these lesions affect, in an equivalent manner, the purine bases and the pyrimidine bases of DNA.
- these lesions mention may be made of 8-oxoguanine, glycols, of thymine, fapy-guanine, fapy-adenine, hydroxymethyl-uracil, 5-hydroxymethyl-cytosine, formyl-uracil (Cadet et al, Rev. Physiol. Biochem. Pharm., 1997, 31, 1.87).
- the main lesions formed are pyrimidine dimers of the cyclobutane type (Costalat et al., Photochem. Photobiol, 1990,51, 255-262). - by releasing energy absorbed directly by the bases of DNA such as ultraviolet B or C. The bonds formed are the pyrimidine dimers of cyclobutane type, the photoproducts (6-4) and the Valence Dewar isomer ( Douki et al., J. Biol. Chem., 2000,275, 11678-11685). - by releasing singlet oxygen. These agents belong, for example, to the family of endoperoxides. The lesion formed in this case is 8-oxoguanine (Ravanat et al, J. Biol. Chem., 2001, 276, 40601-40604).
- the chemical agents are chosen from those which induce modifications of known bases belonging inter alia to the family of carcinogens.
- step (a) of said method different agents are used on each plasmid of said range of plasmids.
- the characterization of the lesions comprises (i) the removal of a fraction of each injured plasmid, (ii) the digestion of each of said fractions with enzymes releasing the nucleosides of DNA, then (iii) the analysis of the result of digestion using a combination of separation techniques coupled with a quantitative analytical technique.
- the digestion is carried out using at least one of the following enzymes: calf spleen phosphodiesterase, PI nuclease, snake venom phosphodiesterase , and alkaline phosphatase (Douki et al., J. Biol. Chem., 2000,275, 11678-11685).
- the result of the enzymatic digestion is analyzed by one of the techniques following: High Performance Liquid Chromatography (HPLC) coupled with Tandem mass spectrometry (Douki et coli, 2000, J. Biol. Chem., 275, 11678- 11685; Sauvaigo et coli, 2001, Photochem. Photobiol., 73, 230-237; Frelon et al., Chem. Res. Tox., 2000, 13, 1002-1010), by HPLC coupled with Gas Chromatography (Wang et coli, 2000, 13, 1149-1157; Pouget et coli, 2000 , Chem. Res. Tox., 13, 541-549) or else by HPLC coupled with electrochemical detection (Pouget et coli, 2000, Chem. Res. Tox., 13, 541-549).
- HPLC High Performance Liquid Chromatography
- Tandem mass spectrometry Douki et coli, 2000, J. Biol. Chem
- the super-coiled forms of the plasmids obtained in step (a) are purified, preferably by centrifugation on a sucrose gradient and / or on cesium chloride gradient.
- each of the plasmids from the range of plasmids is diluted to a concentration of between 5 and 100 ⁇ g / ml, in a dilution buffer comprising preferably a buffer with a pH between 6.5 and 8.0, optionally combined with a salt and a nonionic surfactant; preferably, said buffer is a 10 mM phosphate buffer or an SSC buffer, which may contain 0.05 M to 0.5 M NaCl.
- the various plasmids are preferably deposited using a robot intended for the manufacture of micro-matrices, that is to say that the volumes deposited are preferably between 100 and 1000 pico liters.
- said support is a sensitized support, so as to increase its affinity for DNA, selected from the group consisting of organic or inorganic materials chosen from glass, silicon and its derivatives and synthetic or non-synthetic polymers (nylon or nitrocellulose membranes), the surface of which is optionally functionalized; preferably, said support consists of glass slides coated with poly-L-lysine which adsorb DNA or glass slides functionalized with epoxy groups which form covalent bonds with DNA. If necessary, treatments are carried out so as to increase the binding of the DNA to its support. These treatments must not create additional lesions on the deposited DNA.
- a typical support according to the invention comprising zones Ai to A x , each zone comprising the entire range of plasmids comprises in each of said zones:
- plasmid deposit containing oxidative damage and / or - a plasmid deposit containing etheno-bases, and / or
- the biological extract can be prepared from the biological medium, according to the method of Manley et al., 1983, Methods Enzymol. 101, 568-582 or according to the method of Biade et al., J. Biol. Chem, 1998, 273, 898-902, or by any other method capable of providing a medium containing proteins of the repair.
- the marker is selected from affinity molecules, fluorescent compounds, antibodies or biotin; preferably, the marker or the marker developer is chosen in particular from the group consisting of fluorescent compounds with direct fluorescence (Cy-3 or Cy-5) or indirect (biotin or digoxigenin).
- the support is then incubated at a temperature favoring the repair reaction preferably at 30 ° C for a time between one and five hours, preferably for three hours.
- the support is washed at least once using a saline solution containing a nonionic surfactant, in particular a phosphate buffer 10 mM, containing Tween 20, then is rinsed with water at least once.
- a nonionic surfactant in particular a phosphate buffer 10 mM, containing Tween 20
- the measurement of the signal is carried out by a method suitable for the marker; for example, if the marker is a fluorophore, the fluorescent signals emitted by the various deposits of the support are directly measured.
- said signals are quantified using a device capable of exciting the marker, preferably a fluorophore and of measuring the signal issued following excitement.
- the measurement of the signal is carried out by instrumentation adapted to the support and to the marker used.
- a scanner can be used for image analysis in fluorescence, preferably with laser excitations at the specific wavelength of the marker used.
- step (h) of the method according to the invention a digital relationship is established between the signals obtained with the plasmids containing the lesions and the signal obtained with the control plasmid located on the same support .
- This repair profile can be used to determine the overall and specific repair capacities of an environment, to diagnose a repair-related disease, to assess the influence of a physical or chemical treatment (genotoxic product, for example) on the repair capacities of a given environment.
- the present invention also relates to the use of the method as defined above: - for establishing the repair profile of a biological medium,
- FIG. 1 illustrates an example of configuration of the solid support; there is a deposition plan in nine zones;
- FIG. 3 shows a repair diagram - repair mapping associated with each cell line used to prepare the extract used for the repair reaction.
- Example 1 Preparation of the Plasmid Range and Assay of Lesions
- the plasmid pBluescript II is produced by transformation of the “XLl-Blue MRF supercompetent cells” cells of Stratagene according to the protocol provided by Stratagene.
- the plasmid is then purified using the Qiagen plasmid midi kit, following the recommended protocol. Additional purification of the plasmid
- the plasmid is deposited on 10 ml of 5-20% sucrose gradient in 25 mM Tris HCl buffer pH 7.5; 1 M NaCl; 5 mM EDTA and centrifuged in a Beckman ultra centrifuge using a SW-41 rotor, at 4 ° C at 25,000 rpm for 18 hours. 1 ml fractions are then gently removed and analyzed on agarose gel. Only the fractions containing at least 90% of the coiled form of the plasmid are kept. The plasmid is precipitated with ethanol and dissolved in PBS.
- CCA-Signa Chloroacetaldehyde treatment
- MDA-dG malondialdehyde-deoxyguanine
- plasmid prepared at 1 mg / ml in PB S, an equivalent volume of CAA (50% in H 2 O) is added. This solution is incubated overnight at 37 ° C. The plasmid is recovered by precipitation and purified on a sucrose gradient.
- a fraction of plasmid DNA or of calf thymus DNA treated under the same conditions is taken for analysis of the composition in modified bases.
- the DNA is digested as described by Douki et al, J. Biol. Chem., 275, 11678-11685, then the analysis is performed by HPLC-coupled to tandem mass spectrometry. The following quantity of lesions is obtained for 10 normal bases
- UVCs very widely cause the formation of pyrimidine dimers of cyclobutane type (CPD) and in the majority of photoproducts (6-4), DDE causes the majority of etheno-deoxyguanosine, - endoperoxide causes the overwhelming formation of 8-oxo-2 '- deoxyguanosine.
- Example 2 implementation of the method according to the invention with the range of plasmids prepared in Example 1.
- the plasmids are diluted in PB S to 20 ⁇ g / ml. Deposits of 500 picoliters are carried out using a GESIM robot, on commercial glass slides coated with poly-L-lysine (VWR). The slides are stored at 4 ° C. Each blade (support S) has 9 identical zones (Al to A9) arranged according to diagram A in FIG. 1.
- each zone the range of plasmids is deposited in accordance with FIG. 2, which illustrates for example the zone Al.
- a solution is prepared containing the medium or biological extract to be tested; for 5 ⁇ l of solution, the composition is as follows:
- Composition of the repair pad 5x Hepes / KOH 220 Mm Ph 7.8; MgCl 2 35 mM; 2.5 mM DTT; 2 ⁇ M dATP, 2 ⁇ M dGTP; dCTP 2 ⁇ M; 50 mM phosphocreatine; Creatine phosphokinase 250 ⁇ g / ml; BSA 0.5 mg / ml; glycerol 17%.
- the example is carried out with three different extracts from different cell lines:
- Line 1 these are HeLa cells.
- the extracts are commercial nuclear extracts and come from the company 4C Biotech (Belgium). They were prepared by the method of Dignam et al, (Nucl. Ac. Res., 1983, 11, 1475-1489). Their protein content is 24 mg / ml.
- Line 2 this is an AS203 cell line established from a patient suffering from xeroderma pigmentosum of complementation group D.
- the extracts were prepared according to the protocol of Manley et al.
- the dosage of proteins by the micro BCA kit allows to assess the quantity of proteins at 44 mg / ml.
- Line 3 these are XP12RO cells. This line was established from a patient with complementation group xeroderma pigmentosum
- the extract obtained contains 36 mg / ml of proteins (micro BCA kit, Interchim dosage). 3 ⁇ l of each repair solution are deposited on all of the deposits in a single zone of the slide. The slide is incubated at 30 ° C, at humidity, for
- the HeLa line repairs twice as effectively the lesions induced by DDE (mainly etheno-dG) than by UV (mainly CPD and (6-4)). It is observed that the oxidative damage (mainly 8-oxo-dG) is repaired much more weakly.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004563273A JP4562531B2 (ja) | 2002-12-20 | 2003-12-19 | 少なくとも1つの生物学的媒質の全体dna修復能力及び特異的dna修復能力の定量的評価方法及びその適用 |
EP03799647A EP1576191B1 (fr) | 2002-12-20 | 2003-12-19 | Procede d'evaluation quantitative des capacites globales et specifiques de reparation de l'adn d'au moins un milieu biologique, ainsi que ses applications. |
KR1020057011410A KR101123976B1 (ko) | 2002-12-20 | 2003-12-19 | 하나 이상의 생물학적 매질의 전체 및 특이적 dna 복구 능력의 정량적 평가 방법 및 응용 |
DE60309930T DE60309930T2 (de) | 2002-12-20 | 2003-12-19 | Verfahren zur quantitativen evaluierung der gesamten und spezifischen fähigkeiten zur dns-reparatur mindestens eines biologischen mittels, und dessen anwendungen |
US10/539,769 US20060147929A1 (en) | 2002-12-20 | 2003-12-19 | Method for the quantitative assessment of global and specific dna repair capacities of at least one biological medium, and the applications thereof |
AU2003299364A AU2003299364A1 (en) | 2002-12-20 | 2003-12-19 | Method for the quantitative assessment of global and specific dna repair capacities of at least one biological medium, and the applications thereof |
US14/336,453 US9617580B2 (en) | 2002-12-20 | 2014-07-21 | Method for the quantitative assessment of global and specific DNA repair capacities of at least one biological medium, and the applications therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0216435A FR2849058B1 (fr) | 2002-12-20 | 2002-12-20 | Procede d'evaluation quantitative des capacites globales et specifiques de reparation de l'adn d'au moins un milieu biologique, ainsi que ses applications |
FR0216435 | 2002-12-20 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10539769 A-371-Of-International | 2003-12-19 | ||
US10/539,769 A-371-Of-International US20060147929A1 (en) | 2002-12-20 | 2003-12-19 | Method for the quantitative assessment of global and specific dna repair capacities of at least one biological medium, and the applications thereof |
US14/336,453 Continuation US9617580B2 (en) | 2002-12-20 | 2014-07-21 | Method for the quantitative assessment of global and specific DNA repair capacities of at least one biological medium, and the applications therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004059004A2 true WO2004059004A2 (fr) | 2004-07-15 |
WO2004059004A3 WO2004059004A3 (fr) | 2004-08-19 |
Family
ID=32406334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/003816 WO2004059004A2 (fr) | 2002-12-20 | 2003-12-19 | Procede d'evaluation quantitative des capacites globales et specifiques de reparation de l'adn d'au moins un milieu biologique, ainsi que ses applications |
Country Status (12)
Country | Link |
---|---|
US (2) | US20060147929A1 (fr) |
EP (1) | EP1576191B1 (fr) |
JP (1) | JP4562531B2 (fr) |
KR (1) | KR101123976B1 (fr) |
CN (1) | CN100455674C (fr) |
AT (1) | ATE346171T1 (fr) |
AU (1) | AU2003299364A1 (fr) |
DE (1) | DE60309930T2 (fr) |
ES (1) | ES2276157T3 (fr) |
FR (1) | FR2849058B1 (fr) |
PL (1) | PL384058A1 (fr) |
WO (1) | WO2004059004A2 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007103116A2 (fr) * | 2006-03-02 | 2007-09-13 | Laboratory Corporation Of America Holdings | Procédés et systèmes pour évaluer les facteurs de risques de santé par mesurage des dommages à l'adn et de sa réparation |
CN102031285A (zh) * | 2009-09-28 | 2011-04-27 | 复旦大学 | 一种基于双核微核的dna修复能力检测方法 |
WO2015121596A1 (fr) | 2014-02-17 | 2015-08-20 | Universite Claude Bernard Lyon 1 | Methode predictive pour caracteriser la radiosensibilite et la reaction tissulaire d'un patient envers un rayonnement ionisant therapeutique |
WO2019166731A1 (fr) | 2018-02-27 | 2019-09-06 | Lxrepair | Méthode pour génerer un profil des capacités de réparation de l'adn de cellules tumorales et ses applications |
WO2022184907A1 (fr) | 2021-03-04 | 2022-09-09 | Lxrepair | Dosage quantitatif multiplex des activités de réparation de cassure d'adn double brin dans un milieu biologique et ses applications |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2887261B1 (fr) | 2005-06-20 | 2007-09-14 | Commissariat Energie Atomique | Procede d'immobilisation de l'adn superenroule et utilisation pour analyser la reparation de l'adn |
EP2753716B1 (fr) | 2011-09-08 | 2017-11-01 | Yeda Research and Development Co. Ltd. | Nouveaux biomarqueurs de risque pour le cancer du poumon |
CN110208405A (zh) * | 2019-05-30 | 2019-09-06 | 江苏恒生检测有限公司 | 一种检测水稻上呋虫胺残留的方法 |
WO2021028909A1 (fr) | 2019-08-12 | 2021-02-18 | Yeda Research And Development Co. Ltd. | Test sanguin de réparation de l'adn pour prédire la réponse de patients atteints d'un cancer du poumon à une immunothérapie |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999049080A1 (fr) * | 1998-03-26 | 1999-09-30 | Societe Française De Recherches Et D'investissements (S.F.R.I.) | Procede de detection de lesions de l'adn au moyen de complexes de proteines et elements permettant la mise en oeuvre du procede |
US6309838B1 (en) * | 1997-05-20 | 2001-10-30 | Genolife | Method for detecting qualitative and quantitative alterations in DNA and ligands of said alteration ligands |
US20020022228A1 (en) * | 1998-11-03 | 2002-02-21 | Peter Nehls | Method and test kit for analyzing DNA repair |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000039345A1 (fr) * | 1998-12-30 | 2000-07-06 | Dana-Farber Cancer Institute, Inc. | Reseau de balayage de mutation et methode d'utilisation |
FR2809417B1 (fr) * | 2000-05-24 | 2004-07-30 | Commissariat Energie Atomique | Detection et caracterisation de l'activite de proteines impliquees dans la reparation de lesions de l'adn |
-
2002
- 2002-12-20 FR FR0216435A patent/FR2849058B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-19 AT AT03799647T patent/ATE346171T1/de not_active IP Right Cessation
- 2003-12-19 WO PCT/FR2003/003816 patent/WO2004059004A2/fr active IP Right Grant
- 2003-12-19 PL PL384058A patent/PL384058A1/pl not_active IP Right Cessation
- 2003-12-19 KR KR1020057011410A patent/KR101123976B1/ko active IP Right Grant
- 2003-12-19 ES ES03799647T patent/ES2276157T3/es not_active Expired - Lifetime
- 2003-12-19 JP JP2004563273A patent/JP4562531B2/ja not_active Expired - Fee Related
- 2003-12-19 AU AU2003299364A patent/AU2003299364A1/en not_active Abandoned
- 2003-12-19 EP EP03799647A patent/EP1576191B1/fr not_active Expired - Lifetime
- 2003-12-19 DE DE60309930T patent/DE60309930T2/de not_active Expired - Lifetime
- 2003-12-19 US US10/539,769 patent/US20060147929A1/en not_active Abandoned
- 2003-12-19 CN CNB200380108840XA patent/CN100455674C/zh not_active Expired - Lifetime
-
2014
- 2014-07-21 US US14/336,453 patent/US9617580B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309838B1 (en) * | 1997-05-20 | 2001-10-30 | Genolife | Method for detecting qualitative and quantitative alterations in DNA and ligands of said alteration ligands |
WO1999049080A1 (fr) * | 1998-03-26 | 1999-09-30 | Societe Française De Recherches Et D'investissements (S.F.R.I.) | Procede de detection de lesions de l'adn au moyen de complexes de proteines et elements permettant la mise en oeuvre du procede |
US20020022228A1 (en) * | 1998-11-03 | 2002-02-21 | Peter Nehls | Method and test kit for analyzing DNA repair |
Non-Patent Citations (1)
Title |
---|
WOOD R D ET AL: "COMPLEMENTATION OF THE XERODERMA PIGMENTOSUM DNA REPAIR DEFECT IN CELL-FREE EXTRACTS" CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 53, 8 avril 1988 (1988-04-08), pages 97-106, XP002054959 ISSN: 0092-8674 cité dans la demande * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007103116A2 (fr) * | 2006-03-02 | 2007-09-13 | Laboratory Corporation Of America Holdings | Procédés et systèmes pour évaluer les facteurs de risques de santé par mesurage des dommages à l'adn et de sa réparation |
WO2007103116A3 (fr) * | 2006-03-02 | 2008-02-07 | Lab Corp America Holdings | Procédés et systèmes pour évaluer les facteurs de risques de santé par mesurage des dommages à l'adn et de sa réparation |
CN102031285A (zh) * | 2009-09-28 | 2011-04-27 | 复旦大学 | 一种基于双核微核的dna修复能力检测方法 |
CN102031285B (zh) * | 2009-09-28 | 2016-12-21 | 复旦大学 | 一种基于双核微核的dna修复能力检测方法 |
WO2015121596A1 (fr) | 2014-02-17 | 2015-08-20 | Universite Claude Bernard Lyon 1 | Methode predictive pour caracteriser la radiosensibilite et la reaction tissulaire d'un patient envers un rayonnement ionisant therapeutique |
WO2015121597A1 (fr) | 2014-02-17 | 2015-08-20 | Universite Claude Bernard Lyon 1 | Methode predictive pour determiner la radiosensibilite tissulaire |
WO2019166731A1 (fr) | 2018-02-27 | 2019-09-06 | Lxrepair | Méthode pour génerer un profil des capacités de réparation de l'adn de cellules tumorales et ses applications |
WO2022184907A1 (fr) | 2021-03-04 | 2022-09-09 | Lxrepair | Dosage quantitatif multiplex des activités de réparation de cassure d'adn double brin dans un milieu biologique et ses applications |
Also Published As
Publication number | Publication date |
---|---|
CN100455674C (zh) | 2009-01-28 |
KR20050123090A (ko) | 2005-12-29 |
JP4562531B2 (ja) | 2010-10-13 |
KR101123976B1 (ko) | 2012-03-23 |
JP2006510385A (ja) | 2006-03-30 |
FR2849058A1 (fr) | 2004-06-25 |
US9617580B2 (en) | 2017-04-11 |
AU2003299364A1 (en) | 2004-07-22 |
US20150031580A1 (en) | 2015-01-29 |
DE60309930D1 (de) | 2007-01-04 |
FR2849058B1 (fr) | 2005-02-25 |
DE60309930T2 (de) | 2007-09-20 |
ES2276157T3 (es) | 2007-06-16 |
PL384058A1 (pl) | 2008-06-09 |
ATE346171T1 (de) | 2006-12-15 |
US20060147929A1 (en) | 2006-07-06 |
WO2004059004A3 (fr) | 2004-08-19 |
EP1576191B1 (fr) | 2006-11-22 |
EP1576191A2 (fr) | 2005-09-21 |
CN1738913A (zh) | 2006-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9617580B2 (en) | Method for the quantitative assessment of global and specific DNA repair capacities of at least one biological medium, and the applications therefor | |
US9447454B2 (en) | Method of purifying RNA binding protein-RNA complexes | |
US6403778B1 (en) | Toxicological response markers | |
Czerwińska et al. | ERCC1-deficient cells and mice are hypersensitive to lipid peroxidation | |
Yamasaki et al. | Involvement of lysosomal storage-induced p38 MAP kinase activation in the overproduction of nitric oxide by microglia in cathepsin D-deficient mice | |
WO1998053099A1 (fr) | Procede de detection qualitative et quantitative d'alterations de l'adn et des ligands de ces alterations | |
EP1899485B1 (fr) | Procede d'immobilisation de l'adn superenroule et utilisation pour analyser la reparation de l'adn | |
EP1283911B1 (fr) | Detection et caracterisation de l'activite de proteines impliquees dans la reparation de lesions de l'adn | |
FR2731711A1 (fr) | Procede de detection qualitative et quantitative de lesions de l'adn | |
Sakai et al. | Simultaneous isolation of cell-nuclei, plastid-nuclei and mitochondrial-nuclei from cultured tobacco cells; comparative analysis of their transcriptional activities in vitro | |
WO2019166731A1 (fr) | Méthode pour génerer un profil des capacités de réparation de l'adn de cellules tumorales et ses applications | |
KR100962209B1 (ko) | 말라카이트그린 노출 여부 확인용 바이오마커 및 이를이용한 확인 방법 | |
KR20240072373A (ko) | 편도 유래 줄기세포의 노화 표지 바이오마커 및 이의 용도 | |
FR2836926A1 (fr) | Substrat oligonucleotidique et procede permettant d'analyser la presence d'activites de reparation de lesions de l'adn | |
PLANT | Special Supplement | |
Areshkov et al. | Materials of the 5th Conference of IMBG Young Scientists, dedicated to OO Bogomolets 130th Anniversary (24–25 May 2011) | |
Bobiak | Biochemical Characterization of Human AlkBH7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004563273 Country of ref document: JP Ref document number: 1020057011410 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003799647 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A8840X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 384058 Country of ref document: PL |
|
WWP | Wipo information: published in national office |
Ref document number: 2003799647 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006147929 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10539769 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057011410 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10539769 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003799647 Country of ref document: EP |